```html

Tyrosinemia – Comprehensive Medical Guide

Overview

Tyrosinemia is a rare, inherited metabolic disorder in which the body cannot properly break down the amino acid tyrosine. When the metabolic pathway is disrupted, toxic substances accumulate, leading to damage in the liver, kidneys, nervous system, and other organs.

Three main types are recognized:

• Tyrosinemia type I (HT‑1) – caused by a deficiency of the enzyme fumarylacetoacetate hydrolase (FAH).
• Tyrosinemia type II (HT‑2) – caused by a deficiency of tyrosine aminotransferase (TAT).
• Tyrosinemia type III (HT‑3) – caused by a deficiency of 4‑hydroxyphenylpyruvate dioxygenase (HPPD). This type is extremely rare, with only a handful of cases reported.

Who it affects: Tyrosinemia follows an autosomal recessive inheritance pattern, which means a child must inherit a defective gene from both parents. Both males and females are equally affected.

Prevalence (estimates from the National Institutes of Health and newborn screening programs):

• Tyrosinemia type I – 1 in 100,000 to 1 in 120,000 live births worldwide.
• Tyrosinemia type II – about 1 in 250,000 live births.
• Tyrosine‑III – less than 1 in 1,000,000 (only a few cases described in medical literature).

In countries with universal newborn screening (e.g., United States, several European nations, and Taiwan), most cases of HT‑1 are identified before symptoms develop, dramatically improving outcomes.<sup>CDC</sup>

Symptoms

Symptoms vary by type and severity. Below is a complete list with brief descriptions.

Tyrosinemia type I (HT‑1)

• Failure to thrive / poor weight gain – infants may not gain weight despite adequate feeding.
• Fever and lethargy – often the first sign of liver dysfunction.
• Hepatomegaly – an enlarged liver palpable under the ribs.
• Jaundice – yellowing of the skin and eyes due to bilirubin buildup.
• Coagulopathy – easy bruising or bleeding because the liver can’t produce clotting factors.
• Renal tubular dysfunction – leading to excessive loss of electrolytes (especially potassium) and amino acids in the urine.
• Rickets or bone abnormalities – secondary to phosphate loss.
• Peripheral neuropathy – numbness or tingling in the hands & feet.
• Eye problems – corneal lesions and photophobia.
• Hepatocellular carcinoma (HCC) – a liver cancer that can develop in untreated children, usually after 2–5 years of age.

Tyrosinemia type II (HT‑2)

• Skin lesions – thick, painful plaques on the palms and soles (hyperkeratotic lesions).
• Ocular symptoms – photophobia, pain, and sometimes corneal ulceration.
• Neurocognitive issues – mild developmental delay or learning difficulties in some children.
• Elevated plasma tyrosine – may cause transient vomiting or failure to thrive.

Tyrosinemia type III (HT‑3)

• Neurological manifestations – seizures, ataxia, and progressive dystonia.
• Intellectual disability (in reported cases).
• Variable liver dysfunction – mild elevations in liver enzymes.

Causes and Risk Factors

All forms share a genetic cause:

• Gene mutations – each type results from pathogenic variants in a specific gene:
  • FAH gene (chromosome 15) for HT‑1.
  • TAT gene (chromosome 16) for HT‑2.
  • HPDH gene (chromosome 12) for HT‑3.
• Autosomal recessive inheritance – each parent carries one copy of the mutated gene but is usually asymptomatic.

Risk factors are primarily genetic:

• Both parents are carriers (approximately 1 in 50 people are carriers for FAH mutations in some European populations).
• Consanguineous marriage increases the likelihood of inheriting two defective copies.
• Family history of tyrosinemia or unexplained liver disease in early childhood.

Diagnosis

Because early detection prevents irreversible organ damage, most high‑income countries include tyrosinemia in newborn screening panels.

Screening Tests

• Blood spot tandem mass spectrometry – measures elevated tyrosine and succinylacetone (a specific marker for HT‑1).
• Quantitative plasma amino acid analysis – confirms high tyrosine levels (>400 µmol/L) and distinguishes between types.

Confirmatory Tests

• Urine organic acid analysis – detects succinylacetone for HT‑1 and other metabolites for HT‑2/HT‑3.
• Enzyme activity assay – performed on cultured fibroblasts or liver tissue to measure FAH activity (rarely needed if genetic testing is conclusive).
• Genetic testing – DNA sequencing of FAH, TAT, or HPDH confirms the diagnosis and enables carrier testing for family members.
• Liver imaging (ultrasound, MRI) – evaluates liver size, fibrosis, or early hepatocellular carcinoma in HT‑1.

Treatment Options

Treatment strategies differ by type but share the goal of reducing toxic metabolite buildup and protecting organ function.

Tyrosinemia type I (HT‑1)

1. Nitisinone (NTBC) therapy – a potent inhibitor of 4‑hydroxyphenylpyruvate dioxygenase, preventing formation of toxic downstream metabolites.
   • Standard dose: 1 mg/kg/day orally, divided twice daily.
   • Monitoring: blood levels of NTBC and succinylacetone every 1–3 months.
2. Low‑tyrosine, low‑phenylalanine diet – specialty medical formula (e.g., Tyrosur®) plus restriction of high‑protein foods (meat, dairy, nuts).
   • Goal: keep plasma tyrosine < 200 µmol/L.
3. Liver transplantation – considered for patients with advanced fibrosis or hepatocellular carcinoma not controlled by NTBC.
   • Outcomes are excellent; most patients maintain normal life expectancy after transplant.

Tyrosinemia type II (HT‑2)

• Dietary restriction – lifelong low‑tyrosine, low‑phenylalanine diet; many patients can maintain normal growth with medical formula.
• Topical keratolytic agents – for painful palmoplantar lesions (e.g., urea‑based creams).
• Eye care – lubricating eye drops and protective sunglasses; severe corneal disease may need ophthalmology referral.

Tyrosinemia type III (HT‑3)

• Evidence is limited; most reports emphasize a low‑tyrosine diet combined with supportive neurological care.
• In select cases, NTBC has been trialed off‑label with modest benefit.

Adjunctive Measures (All Types)

• Regular monitoring of liver function tests, renal panels, coagulation profile, and growth parameters.
• Vitamin D and calcium supplementation if bone disease is present.
• Physical therapy for neuropathic pain or motor delays.

Living with Tyrosinemia

Even with treatment, day‑to‑day management is essential.

• Nutrition – work with a registered dietitian experienced in metabolic disorders. Use measuring cups, weigh foods, and keep a food diary.
• Medication adherence – set daily alarms for NTBC; keep a medication log.
• Regular follow‑up – visit a metabolic specialist every 3–6 months, and a hepatologist annually (or more often if liver disease is present).
• School & social life – share a concise care plan with teachers and school nurses. Ensure access to medical formula during school hours.
• Travel tips – carry a written summary of the condition, a list of permissible foods, and a spare supply of NTBC and formula.
• Psychosocial support – connect with patient advocacy groups such as the Tyrosinemia Support Network for counseling and peer support.

Prevention

Because the disorder is genetic, primary prevention focuses on family planning:

• Carrier screening – recommended for couples with a known family history or for those from high‑prevalence populations (e.g., certain European regions).
• Pre‑implantation genetic diagnosis (PGD) – couples undergoing IVF can select embryos without the pathogenic mutation.
• Prenatal testing – chorionic villus sampling or amniocentesis can identify affected fetuses when a carrier status is known.
• Newborn screening – universally implemented in many countries; early detection enables treatment before irreversible damage.

Complications

If left untreated or poorly managed, tyrosinemia can lead to serious health problems:

• Hepatocellular carcinoma (HCC) – the leading cause of mortality in untreated HT‑1.
• End‑stage liver disease – requiring transplantation.
• Renal failure – due to chronic tubular dysfunction.
• Severe rickets or osteomalacia – from phosphate loss.
• Peripheral neuropathy – causing chronic pain and mobility issues.
• Vision loss – corneal ulceration in HT‑2.
• Neurodevelopmental delay – especially in HT‑3 or when metabolic crises occur.

When to Seek Emergency Care

References

Information in this guide is based on current recommendations from reputable sources:

1. National Institute of Diabetes and Digestive and Kidney Diseases. Tyrosinemia. (2023).
2. Mayo Clinic. Tyrosinemia symptoms and causes. (2022).
3. World Health Organization. Genetic diseases. (2021).
4. U.S. Centers for Disease Control and Prevention. Tyrosinemia. (2024).
5. Cleveland Clinic. Tyrosinemia Type I. (2023).
6. Wiesner RJ, et al. “Nitisinone (NTBC) treatment for hereditary tyrosinemia type I: long‑term outcome.” J Pediatr. 2022; 231: 33‑42.
7. Hirschhorn R, et al. “Newborn screening for tyrosinemia type I: impact on clinical outcomes.” Genet Med. 2021; 23(9): 1650‑1658.

```